Jennifer Kayden Lee - 13 Aug 2026 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Reporting relationship: EVP, Head of North America
Issuer ticker: RYTM
Reported as of: 13 Aug 2026
Net transaction value: -$8,901,531
SEC form: 4
Accepted by SEC: 14 Aug 2026, 19:04:44 UTC
Prior SEC filing: 13 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Stephen Vander Stoep, attorney-in-fact for Jennifer Kayden Lee

Key filing fact

Jennifer Kayden Lee filed Form 4 for RHYTHM PHARMACEUTICALS, INC. (RYTM) on 14 Aug 2026.

Key facts

This page summarizes Jennifer Kayden Lee's Form 4 filing for RHYTHM PHARMACEUTICALS, INC. (RYTM).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 14 Aug 2026, 19:04.

Change

Previous filing in this sequence was filed on 13 Feb 2026.
Current net transaction value: -$8,901,531.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001801372 Primary reporting owner

Lee Jennifer Kayden

Relationship: EVP, Head of North America
Address: C/O RHYTHM PHARMACEUTICALS, INC., 222 BERKELEY STREET, 12TH FLOOR, BOSTON
Signature: /s/ Stephen Vander Stoep, attorney-in-fact for Jennifer Kayden Lee
Signature date: 14 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RYTM transaction

Common Stock

Options Exercise

Transaction value
Shares: +35,000
Change %: +182%
Price: $24.29^*
Shares after: 54,233
Date: 13 Aug 2026
Ownership: Direct
Footnotes: F1

RYTM transaction

Common Stock

Options Exercise

Transaction value
Shares: +21,601
Change %: +40%
Price: $6.80^*
Shares after: 75,834
Date: 13 Aug 2026
Ownership: Direct
Footnotes: F1

RYTM transaction

Common Stock

Sale

Transaction value: $8,901,531
Shares: -75,834
Change %: -100%
Price: $117.38
Shares after: 0
Date: 13 Aug 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RYTM transaction Derivative

Stock Options (Right to Buy)

Options Exercise

Transaction value
Shares: -35,000
Change %: -49%
Price: $0.000000^*
Shares after: 36,283
Date: 13 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,000
Exercise price: $24.29
Footnotes: F1, F2

RYTM transaction Derivative

Stock Options (Right to Buy)

Options Exercise

Transaction value
Shares: -21,601
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 13 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 21,601
Exercise price: $6.80
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026.

Footnote F2

The stock options were granted on November 9, 2020. 25% of the shares subject to the option vested and become exercisable on November 9, 2021 and the remaining 75% of the shares subject to the option vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.

Footnote F3

The stock options were granted on February 9, 2022. The options vested and became exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.